JP2023514280A5 - - Google Patents
Info
- Publication number
- JP2023514280A5 JP2023514280A5 JP2022549325A JP2022549325A JP2023514280A5 JP 2023514280 A5 JP2023514280 A5 JP 2023514280A5 JP 2022549325 A JP2022549325 A JP 2022549325A JP 2022549325 A JP2022549325 A JP 2022549325A JP 2023514280 A5 JP2023514280 A5 JP 2023514280A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978692P | 2020-02-19 | 2020-02-19 | |
| US62/978,692 | 2020-02-19 | ||
| PCT/US2021/018863 WO2021168313A1 (en) | 2020-02-19 | 2021-02-19 | Setd2 inhibitors and related methods and uses, including combination therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514280A JP2023514280A (ja) | 2023-04-05 |
| JP2023514280A5 true JP2023514280A5 (https=) | 2024-02-27 |
| JPWO2021168313A5 JPWO2021168313A5 (https=) | 2024-02-27 |
Family
ID=77391740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549325A Pending JP2023514280A (ja) | 2020-02-19 | 2021-02-19 | ｓｅｔｄ２阻害剤、および関連する方法と使用（併用療法を含む） |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230133671A1 (https=) |
| EP (1) | EP4107157A4 (https=) |
| JP (1) | JP2023514280A (https=) |
| KR (1) | KR20220143116A (https=) |
| CN (2) | CN121695288A (https=) |
| AU (1) | AU2021224855A1 (https=) |
| BR (1) | BR112022016573A2 (https=) |
| CA (1) | CA3168069A1 (https=) |
| IL (1) | IL295654A (https=) |
| MX (1) | MX2022010171A (https=) |
| WO (1) | WO2021168313A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530844A (ja) | 2017-08-14 | 2020-10-29 | エピザイム，インコーポレイティド | Ｓｅｔｄ２を阻害することにより癌を処置する方法 |
| CN111093660A (zh) * | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| CN112585119A (zh) | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| US20240299352A1 (en) * | 2021-06-09 | 2024-09-12 | Epizyme, Inc. | Combination therapies with setd2 inhibitors |
| JP2024539726A (ja) * | 2021-11-01 | 2024-10-29 | エピザイム，インコーポレイティド | Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595766A (en) * | 1984-10-26 | 1986-06-17 | Ciba-Geigy Corporation | Process for the preparation of an indoline carboxylic acid |
| US20100035862A1 (en) * | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
| NZ725860A (en) * | 2014-04-04 | 2019-08-30 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| WO2016040505A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Smyd inhibitors |
| CN112585119A (zh) * | 2018-08-14 | 2021-03-30 | Epizyme股份有限公司 | 经取代的吲哚及其使用方法 |
| SG11202105325QA (en) * | 2018-11-30 | 2021-06-29 | Epizyme Inc | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
-
2021
- 2021-02-19 WO PCT/US2021/018863 patent/WO2021168313A1/en not_active Ceased
- 2021-02-19 BR BR112022016573A patent/BR112022016573A2/pt unknown
- 2021-02-19 US US17/904,570 patent/US20230133671A1/en active Pending
- 2021-02-19 CA CA3168069A patent/CA3168069A1/en active Pending
- 2021-02-19 AU AU2021224855A patent/AU2021224855A1/en active Pending
- 2021-02-19 IL IL295654A patent/IL295654A/en unknown
- 2021-02-19 CN CN202511995231.5A patent/CN121695288A/zh active Pending
- 2021-02-19 MX MX2022010171A patent/MX2022010171A/es unknown
- 2021-02-19 EP EP21757967.1A patent/EP4107157A4/en active Pending
- 2021-02-19 CN CN202180028429.XA patent/CN115380033B/zh active Active
- 2021-02-19 JP JP2022549325A patent/JP2023514280A/ja active Pending
- 2021-02-19 KR KR1020227032446A patent/KR20220143116A/ko active Pending